Rebecca S. Muraoka Cook, Ph.D.

Assistant Professor

rebecca.cook@vanderbilt.edu
Faculty Appointments
Assistant Professor of Cell & Developmental Biology Assistant Professor of Biomedical Engineering
Education
Ph.D., Developmental Biology, University of Cincinnati, Cincinnati, OhioB.S., Biology, Vanderbilt University, Nashville, Tennessee
Office Address
759 PRB
2220 Peirce Ave
Nashville, TN 37232-6838
Research Description
Many of the physiologic signaling pathways that contribute to tissue development and function are often comandeered by tumor cells to prmote their own growth and metastasis. It is becoming increasingly clear that signaling pathways necessary for growth of the breast epithelium during puberty and pregnancy, and for breast remodeling after lactation are abnormally activated during various stages of tumor formation and progression. The long-term goal of our research is a greater understanding of these signaling pathways, and how they contribute to both mammary gland physiology and breast cancer.

Much of our research focuses on signaling pathways induced by the ErbB family of receptor tyrosine kinases, which include EGFR, ErbB2, ErbB3, and ErbB4. Evidence suggests that three of these family members, EGFR, ErbB2, and ErbB3, are required for increased growth of the mammary epithelium during puberty and pregnancy. Their pathologic overexpression contributes to breast tumor formation and increased malignancy. Much of our current research examines the specific contributions of ErbB3 to breast cancer progression, and its potential as a therapeutic target in ErbB2-expressing breast cancers.

In contrast, ErbB4 is required for lactational differentiation of the mammary epithelium. The role and prognostic value of ErbB4 in breast cancer remains unclear, and our recently published work is aimed at understanding how ErbB4 expression impacts the behavior of normal mammary epithelial cells. Future studies will build on this work and focus on how ErbB4, and the signaling pathways activated in response to ErbB4, impact growth and progression of mammary tumors.

Finally, remodeling of the mammary gland after lactation ceases, a process known as involution, is a complex process that requires elimination of much of the mammary epithelium, accompanied by a profound level of structural remodling of the mammary stroma. Remodeling of the mammary stroma requires a series of communications between the mammary epithelium and its surrounding stromal environment. Evidence suggests that many of the stromal remodeling events and the signaling pathways that regulate these events are also active in breast tumors, and contribute to the pathology of the disease. Our ongoing research will use models of impaired involution versus sustained involution to determine the impact of involution-specific stromal remodeling events upon homeostasis of the mammary epithelium, and to the growth and metastasis of breast tumors.

Publications
Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. Breast Cancer Res. 2017 Jun 6/30/2017; 19(1): 74. PMID: 28666462, PMCID: PMC5493112, PII: 10.1186/s13058-017-0868-8, DOI: 10.1186/s13058-017-0868-8, ISSN: 1465-542X.

Walsh AJ, Cook RS, Skala MC. Functional Optical Imaging of Primary Human Tumor Organoids for Personalized Drug Screens. J. Nucl. Med [print-electronic]. 2017 Jun 6/6/2017; PMID: 28588148, PII: jnumed.117.192534, DOI: 10.2967/jnumed.117.192534, ISSN: 1535-5667.

Song W, Hwang Y, Youngblood VM, Cook RS, Balko JM, Chen J, Brantley-Sieders DM. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers. Oncogene [print-electronic]. 2017 Jun 6/5/2017; PMID: 28581527, PII: onc2017170, DOI: 10.1038/onc.2017.170, ISSN: 1476-5594.

Kim LC, Cook RS, Chen J. MTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene [print-electronic]. 2017 Apr 4/20/2017; 36(16): 2191-201. PMID: 27748764, PMCID: PMC5393956, PII: onc2016363, DOI: 10.1038/onc.2016.363, ISSN: 1476-5594.

Williams MM, Lee L, Hicks DJ, Joly MM, Elion D, Rahman B, McKernan C, Sanchez V, Balko JM, Stricker T, Estrada MV, Cook RS. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Mol. Cancer Res [print-electronic]. 2017 Mar; 15(3): 259-68. PMID: 28039357, PMCID: PMC5334148, PII: 1541-7786.MCR-16-0280-T, DOI: 10.1158/1541-7786.MCR-16-0280-T, ISSN: 1557-3125.

Morrison Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov dos D, Muller WJ, Brantley-Sieders D, Cook RS. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. Cancer Res [print-electronic]. 2016 Aug 8/15/2016; 76(16): 4752-64. PMID: 27197158, PII: 0008-5472.CAN-15-3393, DOI: 10.1158/0008-5472.CAN-15-3393, ISSN: 1538-7445.

Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Sci Transl Med. 2016 Apr 4/13/2016; 8(334): 334ra53. PMID: 27075627, PMCID: PMC5256931, PII: 8/334/334ra53, DOI: 10.1126/scitranslmed.aad3001, ISSN: 1946-6242.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin. Cancer Res [print-electronic]. 2016 Mar 3/15/2016; 22(6): 1499-509. PMID: 26515496, PMCID: PMC4794351, PII: 1078-0432.CCR-15-1125, DOI: 10.1158/1078-0432.CCR-15-1125, ISSN: 1078-0432.

Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Oncogene [print-electronic]. 2016 Mar 3/3/2016; 35(9): 1143-52. PMID: 26148232, PMCID: PMC4703573, PII: onc2015169, DOI: 10.1038/onc.2015.169, ISSN: 1476-5594.

Manning HC, Buck JR, Cook RS. Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine. J. Nucl. Med. 2016 Feb; 57 Suppl 1: 60S-8S. PMID: 26834104, PII: jnumed.115.157917, DOI: 10.2967/jnumed.115.157917, ISSN: 1535-5667.

Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC. Drug response in organoids generated from frozen primary tumor tissues. Sci Rep. 2016 Jan 1/7/2016; 6: 18889. PMID: 26738962, PMCID: PMC4703961, PII: srep18889, DOI: 10.1038/srep18889, ISSN: 2045-2322.

Young CD, Arteaga CL, Cook RS. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. Breast Cancer Res. 2015 Dec 12/4/2015; 17: 148. PMID: 26637440, PMCID: PMC4670529, PII: 10.1186/s13058-015-0656-2, DOI: 10.1186/s13058-015-0656-2, ISSN: 1465-542X.

Vaught DB, Cook RS. Clearance of dying cells accelerates malignancy [editorial]. Oncotarget. 2015 Sep 9/22/2015; 6(28): 24590-1. PMID: 26387138, PMCID: PMC4694776, PII: 5670, DOI: 10.18632/oncotarget.5670, ISSN: 1949-2553.

Morrison MM, Young CD, Wang S, Sobolik T, Sanchez VM, Hicks DJ, Cook RS, Brantley-Sieders DM. MTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis. PLoS Genet. 2015 Jul; 11(7): e1005291. PMID: 26132202, PMCID: PMC4488502, PII: PGENETICS-D-14-03145, DOI: 10.1371/journal.pgen.1005291, ISSN: 1553-7404.

Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Mol. Cell Proteomics [print-electronic]. 2015 Jul; 14(7): 1959-76. PMID: 25953087, PMCID: PMC4587316, PII: M115.049783, DOI: 10.1074/mcp.M115.049783, ISSN: 1535-9484.

Williams MM, Cook RS. Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?. Oncotarget. 2015 Feb 2/28/2015; 6(6): 3519-30. PMID: 25784482, PMCID: PMC4414133, PII: 2792, DOI: 10.18632/oncotarget.2792, ISSN: 1949-2553.

Walsh AJ, Cook RS, Lee JH, Arteaga CL, Skala MC. Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts. J Biomed Opt. 2015 Feb; 20(2): 26004. PMID: 25700233, PMCID: PMC4335617, PII: 2173302, DOI: 10.1117/1.JBO.20.2.026004, ISSN: 1560-2281.

Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC. Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. Cancer Res [print-electronic]. 2014 Sep 9/15/2014; 74(18): 5184-94. PMID: 25100563, PMCID: PMC4167558, PII: 0008-5472.CAN-14-0663, DOI: 10.1158/0008-5472.CAN-14-0663, ISSN: 1538-7445.

McCormack DR, Walsh AJ, Sit W, Arteaga CL, Chen J, Cook RS, Skala MC. In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts. Biomed Opt Express. 2014 Jul 7/1/2014; 5(7): 2247-61. PMID: 25071962, PMCID: PMC4102362, PII: 210394, DOI: 10.1364/BOE.5.002247, ISSN: 2156-7085.

Sobolik T, Su YJ, Wells S, Ayers GD, Cook RS, Richmond A. CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Mol. Biol. Cell [print-electronic]. 2014 Mar; 25(5): 566-82. PMID: 24403602, PMCID: PMC3937084, PII: mbc.E13-07-0360, DOI: 10.1091/mbc.E13-07-0360, ISSN: 1939-4586.

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov [print-electronic]. 2014 Feb; 4(2): 232-45. PMID: 24356096, PMCID: PMC3946308, PII: 2159-8290.CD-13-0286, DOI: 10.1158/2159-8290.CD-13-0286, ISSN: 2159-8290.

Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Cancer Res. 2013 Oct 10/15/2013; 73(20): 6164-74. PMID: 24130112, PMCID: PMC3801432, PII: 73/20/6164, DOI: 10.1158/0008-5472.CAN-13-0527, ISSN: 1538-7445.

Balko JM, Schwarz LJ, Bhola NE, Kurupi R, Owens P, Miller TW, Gómez H, Cook RS, Arteaga CL. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res [print-electronic]. 2013 Oct 10/15/2013; 73(20): 6346-58. PMID: 23966295, PMCID: PMC4090144, PII: 0008-5472.CAN-13-1385, DOI: 10.1158/0008-5472.CAN-13-1385, ISSN: 1538-7445.

Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2013 Aug 8/27/2013; 110(35): 14372-7. PMID: 23940356, PMCID: PMC3761610, PII: 1303204110, DOI: 10.1073/pnas.1303204110, ISSN: 1091-6490.

Cook RS, Jacobsen KM, Wofford AM, DeRyckere D, Stanford J, Prieto AL, Redente E, Sandahl M, Hunter DM, Strunk KE, Graham DK, Earp HS. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis. J. Clin. Invest [print-electronic]. 2013 Aug; 123(8): 3231-42. PMID: 23867499, PMCID: PMC3726162, PII: 67655, DOI: 10.1172/JCI67655, ISSN: 1558-8238.

Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Res [print-electronic]. 2013 Jul 7/1/2013; 73(13): 4075-85. PMID: 23633485, PMCID: PMC3702683, PII: 0008-5472.CAN-12-4579, DOI: 10.1158/0008-5472.CAN-12-4579, ISSN: 1538-7445.

Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, Stanford J, Cook RS, Arteaga CL. TGF-ß inhibition enhances chemotherapy action against triple-negative breast cancer. J. Clin. Invest [print-electronic]. 2013 Mar; 123(3): 1348-58. PMID: 23391723, PMCID: PMC3582135, PII: 65416, DOI: 10.1172/JCI65416, ISSN: 1558-8238.

Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin. Cancer Res [print-electronic]. 2013 Feb 2/1/2013; 19(3): 610-9. PMID: 23224399, PMCID: PMC3563762, PII: 1078-0432.CCR-12-2024, DOI: 10.1158/1078-0432.CCR-12-2024, ISSN: 1078-0432.

Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 2012 Jul; 18(7): 1052-9. PMID: 22683778, PMCID: PMC3693569, PII: nm.2795, DOI: 10.1038/nm.2795, ISSN: 1546-170X.

Vaught DB, Stanford JC, Young C, Hicks DJ, Wheeler F, Rinehart C, Sánchez V, Koland J, Muller WJ, Arteaga CL, Cook RS. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. Cancer Res [print-electronic]. 2012 May 5/15/2012; 72(10): 2672-82. PMID: 22461506, PMCID: PMC3693553, PII: 0008-5472.CAN-11-3594, DOI: 10.1158/0008-5472.CAN-11-3594, ISSN: 1538-7445.

Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2012 Jan 1/3/2012; 109(1): 221-6. PMID: 22178756, PMCID: PMC3252958, PII: 1115802109, DOI: 10.1073/pnas.1115802109, ISSN: 1091-6490.

Brantley-Sieders DM, Fan KH, Deming-Halverson SL, Shyr Y, Cook RS. Local breast cancer spatial patterning: a tool for community health resource allocation to address local disparities in breast cancer mortality. PLoS ONE [print-electronic]. 2012; 7(9): e45238. PMID: 23028869, PMCID: PMC3460936, PII: PONE-D-12-12178, DOI: 10.1371/journal.pone.0045238, ISSN: 1932-6203.

Walsh A, Cook RS, Rexer B, Arteaga CL, Skala MC. Optical imaging of metabolism in HER2 overexpressing breast cancer cells. Biomed Opt Express [print-electronic]. 2012 Jan 1/1/2012; 3(1): 75-85. PMID: 22254170, PMCID: PMC3255344, PII: 156540, DOI: 10.1364/BOE.3.000075, ISSN: 2156-7085.

Cook RS, Garrett JT, Sánchez V, Stanford JC, Young C, Chakrabarty A, Rinehart C, Zhang Y, Wu Y, Greenberger L, Horak ID, Arteaga CL. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis. Cancer Res [print-electronic]. 2011 Jun 6/1/2011; 71(11): 3941-51. PMID: 21482676, PMCID: PMC3204389, PII: 0008-5472.CAN-10-3775, DOI: 10.1158/0008-5472.CAN-10-3775, ISSN: 1538-7445.

Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL. Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc. Natl. Acad. Sci. U.S.A [print-electronic]. 2011 Mar 3/22/2011; 108(12): 5021-6. PMID: 21385943, PMCID: PMC3064360, PII: 1016140108, DOI: 10.1073/pnas.1016140108, ISSN: 1091-6490.

Dunaway CM, Hwang Y, Lindsley CW, Cook RS, Wu JY, Boothby M, Chen J, Brantley-Sieders DM. Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis. Mol. Cell. Biol [print-electronic]. 2011 Feb; 31(3): 404-16. PMID: 21135133, PMCID: PMC3028625, PII: MCB.00667-10, DOI: 10.1128/MCB.00667-10, ISSN: 1098-5549.

Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL. H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene [print-electronic]. 2010 Sep 9/16/2010; 29(37): 5193-203. PMID: 20581867, PMCID: PMC2945381, PII: onc2010257, DOI: 10.1038/onc.2010.257, ISSN: 1476-5594.

Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, Muraoka-Cook RS, Cheng JQ, Schönbrunn E, Sebti SM, Earp HS, Mahajan NP. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PLoS ONE. 2010; 5(3): e9646. PMID: 20333297, PMCID: PMC2841635, DOI: 10.1371/journal.pone.0009646, ISSN: 1932-6203.

Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C, Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res [print-electronic]. 2010 Jan 1/1/2010; 70(1): 299-308. PMID: 20028874, PMCID: PMC3859619, PII: 0008-5472.CAN-09-1845, DOI: 10.1158/0008-5472.CAN-09-1845, ISSN: 1538-7445.

Miller TW, Forbes JT, Shah C, Wyatt SK, Manning HC, Olivares MG, Sanchez V, Dugger TC, de Matos Granja N, Narasanna A, Cook RS, Kennedy JP, Lindsley CW, Arteaga CL. Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin. Cancer Res [print-electronic]. 2009 Dec 12/1/2009; 15(23): 7266-76. PMID: 19934303, PMCID: PMC2787848, PII: 1078-0432.CCR-09-1665, DOI: 10.1158/1078-0432.CCR-09-1665, ISSN: 1078-0432.

Muraoka-Cook RS, Sandahl MA, Strunk KE, Miraglia LC, Husted C, Hunter DM, Elenius K, Chodosh LA, Earp HS. ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo. Mol. Cell. Biol [print-electronic]. 2009 Sep; 29(18): 4935-48. PMID: 19596786, PMCID: PMC2738276, PII: MCB.01705-08, DOI: 10.1128/MCB.01705-08, ISSN: 1098-5549.

Feng SM, Muraoka-Cook RS, Hunter D, Sandahl MA, Caskey LS, Miyazawa K, Atfi A, Earp HS. The E3 ubiquitin ligase WWP1 selectively targets HER4 and its proteolytically derived signaling isoforms for degradation. Mol. Cell. Biol [print-electronic]. 2009 Feb; 29(3): 892-906. PMID: 19047365, PMCID: PMC2630679, PII: MCB.00595-08, DOI: 10.1128/MCB.00595-08, ISSN: 1098-5549.

Muraoka-Cook RS, Sandahl M, Hunter D, Miraglia L, Earp HS. Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation. Mol. Endocrinol [print-electronic]. 2008 Oct; 22(10): 2307-21. PMID: 18653779, PMCID: PMC2582536, PII: me.2008-0055, DOI: 10.1210/me.2008-0055, ISSN: 0888-8809.

Muraoka-Cook RS, Feng SM, Strunk KE, Earp HS. ErbB4/HER4: role in mammary gland development, differentiation and growth inhibition. J Mammary Gland Biol Neoplasia [print-electronic]. 2008 Jun; 13(2): 235-46. PMID: 18437540, PMCID: PMC3325098, DOI: 10.1007/s10911-008-9080-x, ISSN: 1083-3021.

Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J. Clin. Invest. 2008 Jan; 118(1): 64-78. PMID: 18079969, PMCID: PMC2129239, DOI: 10.1172/JCI33154, ISSN: 0021-9738.

Feng SM, Sartor CI, Hunter D, Zhou H, Yang X, Caskey LS, Dy R, Muraoka-Cook RS, Earp HS. The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation. Mol. Endocrinol [print-electronic]. 2007 Aug; 21(8): 1861-76. PMID: 17505063, PMCID: PMC2917064, PII: me.2006-0101, DOI: 10.1210/me.2006-0101, ISSN: 0888-8809.

Strunk KE, Husted C, Miraglia LC, Sandahl M, Rearick WA, Hunter DM, Earp HS, Muraoka-Cook RS. HER4 D-box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4. Cancer Res. 2007 Jul 7/15/2007; 67(14): 6582-90. PMID: 17638867, PMCID: PMC2917069, PII: 67/14/6582, DOI: 10.1158/0008-5472.CAN-06-4145, ISSN: 0008-5472.

Muraoka-Cook RS, Caskey LS, Sandahl MA, Hunter DM, Husted C, Strunk KE, Sartor CI, Rearick WA, McCall W, Sgagias MK, Cowan KH, Earp HS. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Mol. Cell. Biol. 2006 Sep; 26(17): 6412-24. PMID: 16914727, PMCID: PMC1592831, PII: 26/17/6412, DOI: 10.1128/MCB.01950-05, ISSN: 0270-7306.

Muraoka-Cook RS, Sandahl M, Husted C, Hunter D, Miraglia L, Feng SM, Elenius K, Earp HS. The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. Mol. Biol. Cell [print-electronic]. 2006 Sep; 17(9): 4118-29. PMID: 16837552, PMCID: PMC1556387, PII: E06-02-0101, DOI: 10.1091/mbc.E06-02-0101, ISSN: 1059-1524.

Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, Yingling JM, Zent R, Arteaga CL. Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene [print-electronic]. 2006 Jun 6/8/2006; 25(24): 3408-23. PMID: 16186809, PII: 1208964, DOI: 10.1038/sj.onc.1208964, ISSN: 0950-9232.

Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, Arteaga CL, Neilson EG, Hayward SW, Moses HL. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 2005 Jul 7/28/2005; 24(32): 5053-68. PMID: 15856015, PMCID: PMC3074577, PII: 1208685, DOI: 10.1038/sj.onc.1208685, ISSN: 0950-9232.

Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin. Cancer Res. 2005 Jan 1/15/2005; 11(2 Pt 2): 937s-43s. PMID: 15701890, PII: 11/2/937S, ISSN: 1078-0432.

Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL. Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res. 2004 Dec 12/15/2004; 64(24): 9002-11. PMID: 15604265, PII: 64/24/9002, DOI: 10.1158/0008-5472.CAN-04-2111, ISSN: 0008-5472.

Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol. Cell. Biol. 2003 Dec; 23(23): 8691-703. PMID: 14612410, PMCID: PMC262670, ISSN: 0270-7306.

Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 2002 Oct 10/10/2002; 21(46): 7011-26. PMID: 12370823, DOI: 10.1038/sj.onc.1205679, ISSN: 0950-9232.

Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 2002 Jun; 109(12): 1551-9. PMID: 12070302, PMCID: PMC151012, DOI: 10.1172/JCI15234, ISSN: 0021-9738.

Muraoka RS, Lenferink AE, Law B, Hamilton E, Brantley DM, Roebuck LR, Arteaga CL. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 2002 Apr; 22(7): 2204-19. PMID: 11884607, PMCID: PMC133673, ISSN: 0270-7306.

Muraoka RS, Lenferink AE, Simpson J, Brantley DM, Roebuck LR, Yakes FM, Arteaga CL. Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J. Cell Biol. 2001 May 5/28/2001; 153(5): 917-32. PMID: 11381079, PMCID: PMC2174338, ISSN: 0021-9525.

Brantley DM, Chen CL, Muraoka RS, Bushdid PB, Bradberry JL, Kittrell F, Medina D, Matrisian LM, Kerr LD, Yull FE. Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol. Biol. Cell. 2001 May; 12(5): 1445-55. PMID: 11359934, PMCID: PMC34596, ISSN: 1059-1524.

Brantley DM, Yull FE, Muraoka RS, Hicks DJ, Cook CM, Kerr LD. Dynamic expression and activity of NF-kappaB during post-natal mammary gland morphogenesis. Mech. Dev. 2000 Oct; 97(1-2): 149-55. PMID: 11025216, PII: S0925477300004056, ISSN: 0925-4773.

Muraoka RS, Bushdid PB, Brantley DM, Yull FE, Kerr LD. Mesenchymal expression of nuclear factor-kappaB inhibits epithelial growth and branching in the embryonic chick lung. Dev. Biol. 2000 Sep 9/15/2000; 225(2): 322-38. PMID: 10985853, PII: S0012-1606(00)99824-5, DOI: 10.1006/dbio.2000.9824, ISSN: 0012-1606.

Muraoka RS, Sun WY, Colbert MC, Waltz SE, Witte DP, Degen JL, Friezner Degen SJ. The Ron/STK receptor tyrosine kinase is essential for peri-implantation development in the mouse. J. Clin. Invest. 1999 May; 103(9): 1277-85. PMID: 10225971, PMCID: PMC408470, DOI: 10.1172/JCI6091, ISSN: 0021-9738.

Muraoka RS, Waltz SE, Degen SJ. Expression of hepatocyte growth factor-like protein is repressed by retinoic acid and enhanced by cyclic adenosine 3',5'-monophosphate response element-binding protein (CREB)-binding protein (CBP). Endocrinology. 1999 Jan; 140(1): 187-96. PMID: 9886825, DOI: 10.1210/endo.140.1.6441, ISSN: 0013-7227.

Margolis PA, Cook RL, Earp JA, Lannon CM, Keyes LL, Klein JD. Factors associated with pediatricians' participation in Medicaid in North Carolina. JAMA. 1992 Apr 4/8/1992; 267(14): 1942-6. PMID: 1296580, ISSN: 0098-7484.

Available Postdoctoral Position Details
Posted: 2/1/2013
Post-doctoral position available for recent graduates to understand receptor tyrosine kinase signaling pathways in breast cancer formation and tumor response to therapeutic anti-cancer reagents.